Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07324785
Recruiting Observational

Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis

NCT07324785 · tracked via the Priya Life Science China tracker
Sponsor
Northern Jiangsu People's Hospital
Phase
Observational
Started
2026-01-07
Last updated
2026-02-17

Condition(s) studied

Diabetic Gastroparesis

Study summary

This study is a prospective observational study. The study will explore the correlation between advanced glycation end products and gastric motility disorder in diabetic gastroparesis（DGP) through the collection of blood and gastric tissue samples and relevant data of patients with DGP and control group patients without diabetes history and gastroparesis symptoms.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria for diabetes gastroparesis group: * Meet the diagnostic criteria for diabetes * Presence of symptoms (see assessment of Gastroparesis Cardinal Symptom Index) * Age range from 18 to 75 years old * Voluntarily participate and sign an informed consent form Inclusion Criteria for control group: * No history of diabetes * No symptoms (see assessment of Gastroparesis Cardinal Symptom Index) * Age range from 18 to 75 years old * Voluntarily participate and sign an informed consent form Exclusion Criteria for diabetes gastroparesis group and control group: * Currently taking prokinetic drugs, anticholinergic drugs, and dopamine drugs that may affect gastric motility * Has a history of gastrointestinal surgery * Pregnant or preparing to conceive * There are neurological disorders such as Parkinson's disease that affect gastrointestinal function * Outlet obstruction caused by organic lesions in the pylorus

Primary outcome measure(s)

  • Gastroparesis Cardinal Symptom Index (GCSI) score — The day when the subjects were enrolled
    The Gastroparesis Cardinal Symptom Index (GCSI) is a patient-reported outcome measure used to assess the severity of gastroparesis symptoms. It consists of nine items grouped into three subscales: postprandial fullness/early satiety, nausea/vomiting, and bloating. Patients rate the severity of each symptom on a scale from 0 (no symptom) to 5 (very severe). The GCSI score is calculated as an average score of all three symptom categories. It is a reliable and valid tool for evaluating symptom severity and treatment effectiveness in clinical trials and other studies

Trial sites (1)

FacilityCityRegionStatus
Northern Jiangsu People's Hospital Yangzhou Jiangsu Recruiting

More Northern Jiangsu People's Hospital trials in China

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients Recruiting
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS Recruiting
Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients Recruiting
Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection Recruiting
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function Recruiting

Other trials for the same condition

Washed Microbiota Transplantation for Diabetic Gastroparesis Recruiting
Washed Microbiota Transplantation Alleviates Diabetic Gastrointestinal Motility Disorders: an Efficacy and Safety Study Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07324785 on ClinicalTrials.gov ↗ ← All trials in China